Bob Ingram, the former head of GlaxoWellcome-turned-venture-capital-investor, is joining the board of directors at BioCryst Pharmaceuticals (Nasdaq: BCRX).
The BioCryst post is just the latest of a long list of board membership roles for Ingram, who also is deeply involved in VC firm Hatteras Ventures.
“The Board of Directors and Leadership Team of BioCryst are very pleased to have Bob Ingram join the Company’s Board,” said George Abercrombie, Chairman of the Board of BioCryst. “Bob brings a wealth of pharmaceutical leadership, and public company board experience to the BioCryst Board. We look forward to his insights and contributions as we
work with the BioCryst team to build the leading oral drug rare disease company.”
BioCryst notes that Ingram is “Lead Director of Valeant Pharmaceuticals International and Cree, Inc., and is Chairman of Viamet. He is also a member of the Board of Directors of Regeneron Pharmaceuticals, Inc.”
In a statement, Ingram praised BioCryst:
“Over the last few years, the Leadership Team and Board has made significant progress toward building BioCryst to be the rare disease, oral drug company, based on its successful structure based drug design platform. I look forward to working with the BioCryst organization and Board of Directors to advance the company toward further success in drug development and commercialization for the benefit of patients.”
